Table 1.

Potential clinical applications of OXPHOS inhibitors

CancerSubtypeAssociated gene expressionRef.
Acute myelogenous leukemia (AML)AML stem cellsBCL-2(27)
Chronic lymphocytic leukemia (CLL)Src-sensitive CLL after Src inhibitionAKT(74)
Classical Hodgkin lymphomaNF-κB(25)
Diffuse large B-cell lymphomaHigh OXPHOS expression(26)
BreastRB1(22, 24)
Pancreatic ductal adenocarcinoma (PDAC)PDAC (stem-like) cells↑Ras(29)
Lung adenocarcinoma(18)
NSCLCNSCLC after EGFR inhibitionEGFR(75)
NSCLCOncogenic Kras and loss of LKB1LKB1, oncogenic Kras(35)
Endometrial carcinomaSerous-like endometrialmtDNA copy number alteration(18)
MelanomaHigh OXPHOS expressionPPARGC1A (PGC1α)(34)
MelanomaBRAF mutant after BRAF inhibitionPPARGC1A (PGC1α), BRAF activating mutation(32, 33)
GliomaLow-grade gliomaIDH1 activating mutation(18)
Head and neck, cervix, lung, brain, bowel, prostate, pancreasHypoxic solid tumors(36)